Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Crinetics Pharmaceuticals Inc.
ViroMissile, Inc.
Exelixis
Cedars-Sinai Medical Center
Boston Scientific Corporation
SystImmune Inc.
UNICANCER
University of Sao Paulo